Bisdesmethylhypericin | 60935-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 芘
• 英文名称: Bisdesmethylhypericin
• 英文别名: 5,7,11,18,22,24-hexahydroxyoctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione
• CAS: 60935-17-3
• 化学式: C₂₈H₁₂O₈
• 分子量: 476.398
• InChiKey: LXZKXKDFSAZETR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  36
• 可旋转键数：
  0
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  156
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• ANTHRAQUINONES FOR USE AS RADIOSENSITIZERS IN CANCER TREATMENT
  申请人：Schaffer Moshe

  公开号：US20130267757A1

  公开（公告）日：2013-10-10

  Provided is an a combination therapy including a radiosensitizing agent and radiation, and being effective to inhibit proliferation of cancer stem cells. Further provided is a combination which includes a radiosensitizing agent and radiation, and effectively reduces incidence of at least one of cancer relapse and metastatic cancer in a subject having a cancer, wherein the cancer includes cancer stem cells. Also provided are anthraquinone derivatives for use as radiosensitizing agents in combination with radiations, the combination therapy being cancer specific. Further, the radiosensitizing agents were found to be cancer specific, namely, some being more effective against a cancer type as compared to others.

  提供了一种联合治疗方案，包括放射增敏剂和放射治疗，能够有效抑制癌干细胞的增殖。此外，还提供了一种联合治疗方案，包括放射增敏剂和放射治疗，能够有效降低患有癌症的受试者中至少一种癌症复发和转移的发生率，其中该癌症包括癌干细胞。同时，提供了蒽醌衍生物作为放射增敏剂与放射线联合使用，该联合治疗方案具有癌症特异性。此外，发现放射增敏剂具有癌症特异性，即某些放射增敏剂对某种癌症类型比其他放射增敏剂更有效。